RTK activation/upregulation also represents a mechanism of resistance to other inhibitors of the ERK pathway, subtending, for instance, resistance to BRAF inhibitors in BRAF(V600E) colorectal cancer, where a transient inhibition of pERK by vemurafenib is followed by rapid ERK reactivation through EGFR. This evidence concerns the gene BRAF and colorectal cancer.